glp 1 and autoimmune GLP-1 Drugs Lower Risk of Death by 44% in Obesity Disease Microdosing GLP-1 for autoimmune conditions:

The addition of an acetyl group to L-Tyrosine makes it more bioavailable than supplementing with L-Tyrosine

On-demand access with a CPD certificate on completion

Diabetes Care 15:dc202887 Hiruma S, Shigiyama F, Hisatake S, Mizumura S, Shiraga N, Hori M, Ikeda T, Hirose T, Kumashiro N (2021) A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study

We may have an additional outcome, if we look after those parameters in the future

S., Suezaki, E

Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: global burden of disease study